Diagnostic significance of type IV collagen and hyaluronic acid in the serum of patients with chronic hepatitis C for staging hepatic fibrosis

Terapevticheskii Arkhiv

Volumn 77, Issue 4, 2005, Pages 50-55

  Yuschuk, N D ^a   Znoiko, O O ^a   Safiullina, N Kh ^a   Dudina, K R ^a   Kelli, E I ^a   Klimova, E A ^a   Kashirin, V I ^a   Braginsky, D M ^a   Kushlinsky, N E ^a   Lyubimova, N V ^a   Vasilyev, A Yu ^a   Penkina, T V ^a   Danilin, A G ^a  

^a NONE

Author keywords

Collagen; Hepatic fibrosis; Hepatitis C; Hyaluronic acid

Indexed keywords

COLLAGEN TYPE 4; COLLAGEN TYPE 5; HYALURONIC ACID;

ACUTE HEPATITIS; ADULT; AGED; ARTICLE; BLOOD; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; EVALUATION; FEMALE; HEPATITIS C; HOSPITALIZATION; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; COLLAGEN TYPE IV; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYALURONIC ACID; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 20144370680     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Ueno T., Ide T., Hashimoto O. et al. Long-term follow-up of interferon-treated chronic hepatitis C and serum hepatic fibrosis markers. Hepatogastroenterology 2001; 48 (40): 1124-1128.
2. Gebo K. A., Herlong H. F., Torbenson M. S. et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002; 36 (5, suppl. 1): S161-S172.
3. Cadranel J.-F., Rufat P., Degos F. et al. Practices of liver biopsy in France: Results of a prospective nationwide survey. Hepatology 2000; 32 (3): 477-481.
4. Leroy V., De Traversay C., Barnoud R. et al. Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha. J. Hepatol. 2001; 35 (1): 120-126.
5. Mazzoran I., Tamara G., Mangiarotti M. A. et al. Effects of interferon therapy on fibrosis serum markers in HCV-positive chronic liver disease. J. Gastroenterol. Hepatol. 1998; 10 (2): 125-131.
6. Patel K., Lajoie A., Heaton S. et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J. Gastroenterol. Hepatol. 2003; 18 (3): 253-257.
7. Plevris J. N., Haydon G. H., Simpson K. J. et al. Serum hyaluronan - a non-invasive test for diagnosing liver cirrhosis. J. Gastroenterol. Hepatol. 2000; 12 (10): 1121-1127.
8. Poynard T., Ratziu V., Benmanov Y. et al. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin. Liver Dis. 2000; 20 (1): 47-54.
9. Kojima H., Hongo Y., Harada H. et al. Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon. J. Gastroenterol. Hepatol. 2001; 16 (9): 1015-1021.
10. Saaden S., Greg C., Carey W. D. et al. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33 (1): 196-200.
11. Shimizu I., Omoya T., Takaoka T. et al. Serum amino-terminal propeptide of type III procollagen and 7S domain of type IV collagen correlate with hepatic iron concentration in patients with chronic hepatitis C following alpha-interferon therapy. J. Gastroenterol. Hepatol. 2001; 16 (2): 196-201.